The state of dietary supplement adverse event reporting in the United States

被引:55
作者
Gardiner, Paula [1 ]
Sarma, Dandapantula N. [2 ]
Dog, Tieraona Low [1 ]
Barrett, Marilyn L. [1 ]
Chavez, Mary L. [1 ]
Ko, Richard [1 ]
Mahady, Gail B. [1 ]
Marles, Robin J. [1 ]
Pellicore, Linda S. [1 ]
Giancaspro, Gabriel I. [2 ]
机构
[1] USP Dietary Supplements Informat Expert Comm, Rockville, MD USA
[2] US Pharmacopeia, Rockville, MD USA
关键词
dietary supplements; adverse event reporting;
D O I
10.1002/pds.1627
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose The Dietary Supplements Information Expert Committee (DSI-EC; the Committee) of the United States Pharmacopeial Convention (USP) reviews safety profiles of dietary supplements before development of USP-National Formulary (USP-NF) quality monographs. Because the veracity of dietary supplement adverse event reports (DS AERs) directly affects DSI-EC safety reviews, the Committee reviewed the current status of DS AER reporting in the US. Methods DSI-EC reviewed PubMed searches, information from the US Food and Drug Administration's (FDA) MedWatch program, the Toxic Exposure Surveillance System (TESS) of the American Association of Poison Control Centers (AAPCC), and reports from US and other agencies. DSI-EC analyzed this information to identify key factors that affect the quality of DS AERs. Results The overall incidence of DS AERs appears generally to be low. However, the primary reporting portal (FDA MedWatch) receives fewer AERs than do poison control centers (PCCs), and limited coordination exists among national and international surveillance programs for evaluating signals that may indicate potential public health risks. Both inadequate and poor-quality reporting of DS AERs are major limitations of DS safety monitoring in the US. Conclusions Based on its assessments, the Committee advances recommendations to improve the quality of reporting, monitoring, and assessing DS AERs. These include (1) enhanced data collection approaches, (2) improved coordination of AER surveillance programs, (3) strengthening of educational programs for public and health care sectors, and (4) conduct of research concerning the safety of DS. If taken, these approaches are expected to improve the health and well-being of DS users. Copyright (C) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:962 / 970
页数:9
相关论文
共 57 条
  • [1] ATWATER J, 2005, US PHARM, V30, P61
  • [2] Barnes Patricia M, 2004, Adv Data, P1
  • [3] Berman B M, 1995, J Am Board Fam Pract, V8, P361
  • [4] Betz JM, 2001, J AOAC INT, V84, P214
  • [5] The value of USP public standards for therapeutic products
    Bhattacharyya, L
    Cecil, T
    Dabbah, R
    Roll, D
    Schuber, S
    Sheinin, EB
    Williams, RL
    [J]. PHARMACEUTICAL RESEARCH, 2004, 21 (10) : 1725 - 1731
  • [6] COMPARISON OF 2 RECENTLY PUBLISHED ALGORITHMS FOR ASSESSING THE PROBABILITY OF ADVERSE DRUG-REACTIONS
    BUSTO, U
    NARANJO, CA
    SELLERS, EM
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 13 (02) : 223 - 227
  • [7] Aristolochic acids detected in some raw chinese medicinal herbs and manufactured herbal products - A consequence of inappropriate nomenclature and imprecise labelling?
    Cheung, Thomas P.
    Xue, Charlie
    Leung, Kelvin
    Chan, Kelvin
    Li, Chun G.
    [J]. CLINICAL TOXICOLOGY, 2006, 44 (04) : 371 - 378
  • [8] European regulations on nutraceuticals, dietary supplements and functional foods: A framework based on safety
    Coppens, P
    da Silva, MF
    Pettman, S
    [J]. TOXICOLOGY, 2006, 221 (01) : 59 - 74
  • [9] Dietary supplement-related adverse events reported to the california poison control system
    Dennehy, CE
    Tsourounis, C
    Horn, AJ
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (14) : 1476 - 1482
  • [10] DESMET P, 1996, DRUG INTERACTIONS, P327